Iraq remains a significant pharmaceutical market in the Middle East, attractive to multinational and regional manufacturers seeking regional growth. The country combines a substantial population, growing private demand, and meaningful unmet medical need with a regulatory and commercial environment that rewards companies willing to engage seriously with local conditions. Successful entry, however, requires careful structuring of legal and commercial arrangements to comply with sector-specific rules and broader Iraqi commercial law. The decisions made at the entry stage shape almost everything that follows: how products can be registered, how supply chains are organized, how disputes are resolved, and how; if necessary, the company can eventually exit.
Market Entry Options
Foreign pharmaceutical companies have several entry routes available, and the choice between them depends on commercial scale, expected duration of presence, level of operational control desired, and willingness to invest in local infrastructure. The principal options are: appointing a local commercial agent, establishing a scientific office, forming a local subsidiary, registering a branch of the foreign company, or entering a joint venture with an Iraqi partner. Many companies use a combination of these; for example, a scientific office for regulatory purposes alongside a commercial agency for distribution and the optimal mix evolves as the business grows.
Commercial Agent
Appointing a local commercial agent is the most common entry route, particularly at early stages of market penetration. Commercial agency in Iraq is governed by the Iraqi Commercial Agency Law, and the agency must be registered with the Ministry of Trade to take legal effect. A registered agent enjoys statutory protections, including the potential for termination compensation that can be significant if the agency is ended without good cause. The scope of authority granted to the agent, exclusivity, performance benchmarks, the term, and the grounds and consequences of termination are all matters that should be addressed carefully in the agency contract, the default rules under Iraqi law are agent-protective in important respects, and contractual drafting that does not account for this often leaves the foreign principal in a weaker position than expected when the relationship sours.
Scientific Office
Establishing a scientific office is a separate and regulatory-driven step, distinct from the commercial agency. A scientific office is recognized by the Ministry of Health as the technical representative of a foreign pharmaceutical manufacturer for purposes of product registration, pharmacovigilance, scientific promotion, and medical liaison. Licensing requires premises that meet inspection standards, a qualified Iraqi pharmacist as responsible technical director, financial guarantees, and a power of attorney from the foreign manufacturer. A foreign manufacturer cannot register its products with the IDCD without involvement of a licensed scientific office, which means that this step is effectively mandatory for any company seeking to market registered pharmaceuticals in Iraq.
Subsidiary or Branch
Forming a local subsidiary, typically a limited liability company under the Iraqi Companies Law No. 21 of 1997 (as amended), gives the foreign company direct presence in Iraq. Subsidiaries may be wholly foreign-owned in the pharmaceutical sector, as in most sectors, and can hold scientific office licenses and engage in import, distribution, and other regulated activities directly. Registration involves the Companies Registrar, tax registration, social security registration, and sector-specific licenses. Registering a branch of the foreign company is another option, although branches are most often used for service-oriented activities, and their suitability for full pharmaceutical operations should be considered against the alternatives in light of taxation, liability, and operational considerations.
Joint Ventures
Joint ventures with Iraqi partners offer access to local market knowledge, established relationships, and operational assets, and they are particularly common in manufacturing or large-scale distribution projects. They also introduce governance, profit-sharing, and dispute risk that needs to be carefully addressed in shareholder agreements and ancillary contracts.
Compliance Across the Stack
Across all entry routes, the foreign pharmaceutical company must comply with the full stack of Iraqi pharmaceutical laws (registration, pricing, advertising, distribution) and general Iraqi law on tax, employment, and exchange control. Corporate tax, withholding tax on payments to foreign principals, customs duties on imported pharmaceuticals, and treaty considerations all interact with the chosen structure in ways that should be modeled before commitments are made. Iraqi employment law applies to local staff and includes specific protections that should be reflected in employment agreements and HR practices. Exchange control and banking regulations affect how funds move into and out of the country.
Anti-Corruption
Anti-corruption compliance deserves particular attention given the realities of doing pharmaceutical business in Iraq, where interactions with public officials, government hospitals, and public procurement bodies are routine. Foreign companies are typically subject to the extraterritorial reach of laws such as the US Foreign Corrupt Practices Act and the UK Bribery Act, in addition to Iraqi anti-corruption law. A compliance program covering due diligence on agents and consultants, clear policies on gifts and hospitality, training of personnel, monitoring of high-risk transactions, and contract clauses requiring compliance and audit rights is essential. Investigations under these laws are expensive and damaging even when they end without prosecution, and prevention is significantly cheaper than response.
Termination and Exit
Termination and exit planning should be addressed from the start, not at the end. Agency arrangements may carry termination indemnities, scientific office relationships involve regulatory transitions that affect product availability, and joint ventures require carefully drafted exit mechanisms that anticipate deadlocks, defaults, and changes of control. Without forward-looking planning, the cost and complexity of exit can be disproportionate to the cost of original entry, and we have seen many situations where companies pay more to leave Iraq cleanly than they ever paid to enter.
How We Can Help
Etihad Law Firm regularly advises foreign pharmaceutical companies on the full lifecycle of market entry into Iraq from initial structuring decisions and partner selection, through negotiation and registration of agency, distribution, scientific office, and joint venture arrangements, to ongoing regulatory and compliance support and the management of disputes and exits.